British medical technology company Smith+Nephew has introduced its RENASYS EDGE negative pressure wound therapy (NPWT) system in the US, for treating chronic wounds.

RENASYS EDGE is a lightweight, compact system that can be easily carried or worn, features a discreet canister, and operates without noise.

The system is designed for patients suffering from chronic wounds and living at home.

As part of the commercial launch, Smith+Nephew announced two new national distribution partners for the RENASYS EDGE System, SunMED Medical Solutions and First Nation Group.

The new partners will help the medical device maker distribute its new technology to more patients and support its growing negative pressure wound therapy business.

Smith+Nephew NPWT vice president and general manager Laura Ackerman said: “When designing the RENASYS EDGE System we kept patients and their needs in the forefront of our minds. It’s the very definition of our purpose – Life Unlimited – allowing patients to continue with their daily lives while receiving prescribed negative pressure wound therapy.

“And now with SunMED in the commercial healthcare market and First Nation Group supporting our veterans, RENASYS EDGE will be able to create a lasting impact on the way patients experience the benefit of negative pressure wound therapy in the comfort of their home.”

According to Smith+Nephew, chronic wounds have a huge impact on a patient’s life, with 68% often becoming self-conscious of their wound and many becoming isolated.

The need to carry a bulky, noisy medical device that draws attention to their condition increases their discomfort.

Its easy-to-use RENASYS EDGE system comes with a user-friendly interface and provides step-by-step guidance on therapy applications.

Also, the system provides technical support with just one click during set-up with the near-field communication feature, said the medical device company.

In November last year, Smith+Nephew agreed to acquire Israeli medical device manufacturer CartiHeal for an initial consideration of $180m plus additional payments of up to $150m.